People · Operator
Named in public records as an officer, director or promoter · active 2019–2020 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Axon Therapies Inc. | — | Other Technology | Series A | $10.8M | $208.0M | 2019 |
| ARTMS Inc. | — | Biotechnology | Series A | $4.8M | $174.7M | 2020 |
Steven S. Hochberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven S. Hochberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mitchell S. Bloom | 1 | 7 |
| Paul S. LaViolette | 1 | 3 |
| Andrew S. ElBardissi | 1 | 2 |
| Mark R. Gelfand | 1 | 2 |
| Steven S. Foster | 1 | 1 |
| Charles S. Conroy | 1 | 1 |
| Michael S. Cross | 1 | 1 |
| Imran S. Eba | 1 | 1 |
| Howard R. Levin | 1 | 1 |
| Paul S. Schaffer | 1 | 1 |
| Karimah S. Es Sabar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.